Company: INMB
Filing Date: 2025-04-21
Form Type: DEF 14A
Source: 0001213900-25-033742
Chunk: 23

Company: Inmune Bio, Inc.
Filing Date: 2025-04-21
Form: DEF 14A
Chunk 23
---
 to a tax deduction in connection with an award under the Second Amended and Restated 2021 Stock Plan in an amount equal to the ordinary income realized by a participant and at the time the participant recognizes such income (for example, the exercise of a nonstatutory stock option). Securities Authorized for Issuance Under Equity Compensation Plans Equity Compensation Plan Information The following table provides certain information with respect to all of our compensation plans in effect as of December 31, 2024:

| Plan Category                                          |     |              (A) 
        Number of 
 Securities to be 
      Issued Upon 
      Exercise of 
      Outstanding 
         Options, 
         Warrants 
       and Rights |      |     | (B)         
 Weighted    
 Average     
 Exercise    
 Price of    
 Outstanding 
 Options,    
 Warrants    
 and Rights  |      |     |              (C) 
        Number of 
       Securities 
        Remaining 
        Available 
       for Future 
         Issuance 
     Under Equity 
     Compensation 
 Plans (excluding 
       securities 
     reflected in 
       column(A)) |      |
|:-------------------------------------------------------|:----|-----------------:|:-----|:----|:------------|-----:|:----|-----------------:|:-----|
| Equity Compensation Plans approved by stockholders     |     |        7,203,307 | ​(1) |     | $           | 8.29 |     |          121,243 | ​(2) |
| Equity Compensation Plans not approved by stockholders |     |                — |      |     |             |    — |     |                — |      |
| Total                                                  |     |        7,203,307 |      |     | $           | 8.29 |     |          121,243 |      |

____________ (1)Consists of shares subject to outstanding stock options, under the Second Amended and Restated 2021 Stock Plan, the 2019 Stock Incentive Plan (the “2019 Plan”) and INmune Bio Inc. 2017 Stock Incentive Plan (the “2017 Plan”) some of which are vested and some of which remain subject to the vesting of the respective equity award. (2)Consists of shares available for future issuance under the Second Amended and Restated 2021 Stock Plan. OUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE
“ FOR ” THIS PROPOSAL NO.